Riskpilot← Back to searchSign inGet full accessAKVAPHARMA AS
ASActiveOrg 825284672Lundeveien 171, 4550 FarsundManufacture of instruments and appliances for measuring, testing and navigation · NACE 2651Est. 20200 employees
Revenue 2024
NOK 0
EBITDA margin
—
-33% vs 2023
Equity ratio
-73.0%
Financial strength
Net profit 2024
NOK -21K
-33% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -21K | -33% |
| Net profit | NOK -21K | -33% |
| Total assets | NOK 52K | +0% |
| Equity | NOK -38K | -120% |
| Employees | 0 | — |
Legal name
AKVAPHARMA AS
Org number
825284672
Legal form
Aksjeselskap
NACE code
2651 · Manufacture of instruments and appliances for measuring, testing and navigation
Founded
2. juli 2020
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikling og salg av utstyr til landbasert akvakultur og forvalte aksjer i andre selskaper og andre produkter som naturlig faller sammen med dette. Herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender.
Address
Lundeveien 171, 4550 Farsund
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −2 | −11 | −14 | −16 | −21 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −2 | −11 | −14 | −16 | −21 |
| Net financials | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −2 | −11 | −14 | −16 | −21 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 | −11 | −14 | −16 | −21 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 43 | 54 | 53 | 53 | 52 |
| Equity | 23 | 12 | −2 | −17 | −38 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 20 | 42 | 55 | 70 | 91 |
| Total debt | 20 | 42 | 55 | 70 | 91 |
EBITDA margin
-2087300.0%
This company
15.8%
Market median
-13210859% vs market
20202024
Equity ratio
-73.0%
This company
38.2%
Market median
-291% vs market
20202024
Return on equity
-2087300.0%
This company
18.4%
Market median
-11344122% vs market
20202024
Net profit margin
-2087300.0%
This company
8.1%
Market median
-25769236% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
2.37×
This company
0.62×
Market median
-282% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-05-08 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EW Accountant | Accountant | 2020 | — | — |
AM Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Landbasert Akvakultur Norge As | Company | 50.0% | 50.0% | 2024 |
Karistua As | Company | 25.0% | 25.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bilbo Utvikling As
AKVAPHARMA AS Board members of AKVAPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Egil Willumsen | Accountant | 0 companies |
| Arne Marthinsen | Chief Executive Officer | 0 companies |
| Arnt Gaute Ubostad | Chairman | 0 companies |
| Jan Erik Unhammer | Board of Directors | 0 companies |